|
Postdoctoral Scientist
Federal University of Minas Gerais (UFMG), Brazil
Email: camilasimoesf@gmail.com
VALIDATE Role:
Network Affiliate
Research Keywords:
Leishmaniasis, Treatment, Vaccines, Diagnostics, Animal Models
Biography:
My research focuses on the development of vaccines, diagnostics, and treatments for neglected tropical diseases, with a primary emphasis on Leishmania spp. I have experience in advanced molecular biology and immunology techniques, including recombinant protein production, immunoenzymatic assays, and synthetic molecule evaluation. My work has involved conducting in vitro and in vivo experiments to investigate therapeutic strategies and immune responses.
My main research interests lie in understanding the host-pathogen interactions and immune mechanisms underlying leishmaniasis and leveraging this knowledge to design effective treatments, vaccines and diagnostic tools. I am also passionate about translational science, aiming to bridge the gap between laboratory research and real-world applications. Beyond leishmaniasis, I have contributed to projects on microbial resistance and diagnostic innovation, reflecting my broader commitment to addressing complex global health challenges through interdisciplinary approaches.
Related Websites:
ResearchGate
LinkedIn
Key Publications:
- Freitas, C. S., Câmara, R. S. B., et al. Urine and serum-based ELISA using a recombinant protein and synthetic peptide for the diagnosis of tegumentary leishmaniasis, Diagnostic Microbiology and Infectious Disease, Volume 111, Issue 3, 2025, 116631, ISSN 0732-8893. https://doi.org/10.1016/j.diagmicrobio.2024.116631
- Freitas, C. S.; PEREIRA, ISABELA A.G. ; et al. New synthetic molecules incorporated into polymeric micelles used for treatment against visceral leishmaniasis. CYTOKINE, v. 177, p. 156543, 2024. https://doi.org/10.1016/j.cyto.2024.156543
- Freitas, C. S., Lage, D. P., Machado, A. S., et al. Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasis. Cytokine, volume 164 (2023). https://doi.org/10.1016/j.cyto.2023.156143
- Freitas, C. S., Santiago, S. S., Lage, D. P., et al. In vitro evaluation of antileishmanial activity, mode of action and cellular response induced by vanillin synthetic derivatives against Leishmania species able to cause cutaneous and visceral leishmaniasis. Experimental Parasitology, volume 251 (2023). https://doi.org/10.1016/j.exppara.2023.108555
- Freitas, C.S., Oliveira-da-Silva, J.A., Lage, D.P. et al. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis. Parasitol Res 120, 321–335 (2021). https://doi.org/10.1007/s00436-020-06971-2
- Freitas CS, Lage DP, Oliveira-da-Silva JA, Costa RR, et. al. In vitro and in vivo antileishmanial activity of b-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis. Parasite 28, 38 (2021). DOI: 10.1051/parasite/2021036
|
